Fig. 8: BRPF1 regulated the expression of downstream targets through epigenetic modification.
From: Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer
a BRPF1 expression was positively correlated with the expression of E2F2 (R2 = 0.1732, P < 0.0001, linear regression) and EZH2 (R2 = 0.2403, P < 0.0001, linear regression) respectively in TCGA HCC cohort. n = 50 b The mRNA expression of E2F2 and EZH2 was reduced in MHCC97L cells siRNA-mediated BRPF1 knockdown. c H3K9 acetylation levels at the promoters of E2F2 and EZH2 remained unchanged after 48-h of GSK5959 treatment in MHCC97L cells. d H3K14 acetylation levels at the promoters of E2F2 and EZH2 were reduced upon 48-h of GSK5959 treatment in MHCC97L cells. e H3K23 acetylation level at the promoters of E2F2 and EZH2 remained unchanged after 48-h of GSK5959 treatment in MHCC97L cells. All acetylation levels were normalized by histone H3 occupancy level. f GSK5959 had no effect on the global levels of H3K9, H3K14, and H3K23 acetylation in MHCC97L cells after 5-days treatment. Error bars indicate mean ± SD. Data were compared by independent t-test unless indicated otherwise. Results were repeated at least three times. **P < 0.01, ***P < 0.001, ****P < 0.0001, ns not significant vs siNTC or IgG ChIP as indicated.
